RIGL (STOCKS)
Rigel Pharmaceuticals Inc. (New)
$34.220000
-0.720000 (-2.06%)
Prev close: $34.940000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Raul R. Rodriguez
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $620.78M
- Employees
- 164
- P/E (TTM)
- 5.67
- P/B (TTM)
- 5.39
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
4
Strong Buy
4
Buy
4
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$1.46 | $0.87 | +0.5882 | +67.47% |
|
Jun 2025 (Q2)
|
$3.28 | $2.63 | +0.6484 | +24.64% |
|
Mar 2025 (Q1)
|
$0.63 | $0.09 | +0.5390 | +592.31% |
|
Dec 2024 (Q4)
|
$0.80 | $0.48 | +0.3237 | +67.96% |
Financial Statements
| Revenues | $282.08M |
| Benefits Costs and Expenses | $167.74M |
| Cost Of Revenue | $19.46M |
| Costs And Expenses | $163.13M |
| Gross Profit | $262.62M |
| Operating Expenses | $143.67M |
| Selling, General, and Administrative Expenses | $115.43M |
| Other Operating Expenses | $28.24M |
| Operating Income/Loss | $118.95M |
| Income/Loss From Continuing Operations After Tax | $113.30M |
| Income/Loss From Continuing Operations Before Tax | $114.34M |
| Income Tax Expense/Benefit | $1.04M |
| Interest Expense, Operating | $7.58M |
| Net Income/Loss | $113.30M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $113.30M |
| Net Income/Loss Available To Common Stockholders, Basic | $113.30M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $6.33 |
| Diluted Earnings Per Share | $6.19 |
| Basic Average Shares | 17,935,000 |
| Diluted Average Shares | 18,467,000 |
| Assets | $242.53M |
| Current Assets | $214.93M |
| Cash | $137.20M |
| Inventory | $13.30M |
| Other Current Assets | $64.42M |
| Noncurrent Assets | $27.61M |
| Fixed Assets | $54.00K |
| Other Non-current Assets | $27.55M |
| Liabilities | $124.93M |
| Current Liabilities | $94.40M |
| Accounts Payable | $3.85M |
| Wages | $10.07M |
| Other Current Liabilities | $80.49M |
| Noncurrent Liabilities | $30.53M |
| Long-term Debt | $60.00M |
| Equity | $117.61M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $117.61M |
| Liabilities And Equity | $242.53M |
| Net Cash Flow From Operating Activities | $68.18M |
| Net Cash Flow From Operating Activities, Continuing | $68.18M |
| Net Cash Flow From Investing Activities | -$77.92M |
| Net Cash Flow From Investing Activities, Continuing | -$77.92M |
| Net Cash Flow From Financing Activities | $6.64M |
| Net Cash Flow From Financing Activities, Continuing | $6.64M |
| Net Cash Flow | -$3.10M |
| Net Cash Flow, Continuing | -$3.10M |
| Comprehensive Income/Loss | $113.39M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $113.39M |
| Other Comprehensive Income/Loss | $85.00K |